MBRX News and Press, Moleculin Biotech Inc. From 05/13/24

Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire – Recently announced interim data from ongoing MB-106 study demonstrating Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1 st an...

Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...

Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin PR Newswire Patent, once issued, will provide composition protection through 2040, with potential for additional term extension Annamycin is advancing towards pivo...

Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast PR Newswire HOUSTON , May 8, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceu...

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data PR Newswire Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 62% (54% CR) in 1 st and 2 nd line AML subjects (N=13) ...

Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024 PR Newswire Live video webcast roundtable with members from the Moleculin Management Team and Dr. Tallman to discuss the unmet medical needs in the ...

Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin PR Newswire – Company appoints internationally renowned clinician, Martin S. Tallman , MD as inaugural clinician member HOUSTON , May 1, 2024 /PRNewswire/ --...

Moleculin CEO, Walter Klemp highlights Annamycin differentiation in the current AML treatment landscape and potential opportunity FRENCHTOWN, NJ / ACCESSWIRE / April 25, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Vir...

2024-04-18 09:13:59 ET More on Moleculin Biotech Moleculin Biotech, Inc. (MBRX) Q4 2023 Earnings Call Transcript Moleculin gets U.S. patent issue notification for annamycin targeting unmet need in AML Seeking Alpha’s Quant Rating on Moleculin Biotech H...

European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML) PR Newswire – Next-generation non-cardiotoxic anthracycline Annamycin with notable signs of clinical efficacy in AML in combination with Cytarabine a...